Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) shares passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.03 and traded as high as $0.06. Mateon Therapeutics shares last traded at $0.06, with a volume of 161,591 shares.
Mateon Therapeutics Stock Down 3.0 %
The business has a fifty day moving average price of $0.04 and a 200-day moving average price of $0.03.
About Mateon Therapeutics
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Further Reading
- Five stocks we like better than Mateon Therapeutics
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
- What Are Dividend Champions? How to Invest in the Champions
- 3 ETFs to Ride the VIX Surge During Market Volatility
- 3 Best Fintech Stocks for a Portfolio Boost
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
